The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

August 12, 2016 • By Martin Garber, DO

  • Tweet
  • Email
Print-Friendly Version / Save PDF
g0d4ather/shutterstock.com

g0d4ather/shutterstock.com

When uric acid becomes elevated in the human body, a variety of problems can develop, most notably gout—a painful, inflammatory arthritis caused by uric acid crystal deposition in joints. Chronically elevated uric acid can also lead to painful kidney stones. The majority of patients found to have hyperuricemia, however, never go on to develop gout or nephrolithiasis, and unless tested, they would never know. Therefore, asymptomatic hyperuricemia is not considered a disease, and treatment has not been indicated. In the early 1980s, uric acid was removed from routine metabolic chemistry blood panels because of this.

You Might Also Like
  • Letter: Should We Monitor Asymptomatic Hyperuricemia?
  • Apolipoprotein E Polymorphism Associated with Hyperuricemia in Chinese Population
  • Weight Loss Surgery May Reduce Risk of Developing Gout
Explore This Issue
August 2016

Evidence is growing that chronically elevated serum uric acid can contribute to a variety of health problems, including type II diabetes, hypertension, vascular disease and chronic kidney disease. Treatment of hyperuricemia may therefore—at least theoretically—result in beneficial risk reduction for these diseases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pathophysiology, Diet & Evolution

In humans, uric acid is the end product of purine catabolism. Two-thirds of uric acid is derived endogenously from normal cell breakdown and one-third from dietary intake. Hyperuricemia is defined as a serum level >7.0 mg/dL. Uric acid elevation early in life (primary hyperuricemia) in most patients is due to decreased renal urate clearance and a smaller percentage from overproduction. The prevalence of hyperuricemia in adult men is 20–25% and much less (4–6%) in premenopausal women (thought to be due to estrogen-induced increased renal urate clearance).1 The prevalence of gout in these patients is only around 4%. The risk of developing gout depends on the duration and level of hyperuricemia. Levels >9.0 pose a significant risk.2

Hyperuricemia tends to begin around puberty, but clinical manifestations, if they do occur, take on average 20 years to develop.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Since the 1960s, the prevalence of both hyperuricemia and gout has more than doubled.3 During this same period, the incidence of type II diabetes, metabolic syndrome and obesity has similarly increased.4 These increases are likely related to lifestyle and dietary factors, including inactivity, obesity, sugars (particularly fructose) and purine-rich fatty food.5

The intake of added sugars to the Western diet, particularly table sugar and high-fructose corn syrup, has greatly increased in the past hundred years. Metabolic syndrome is characterized by hyperglycemia, dyslipidemia and hypertension and its clinical consequence of insulin resistance. Fructose is a major component of added sugars, and its consumption has been directly linked to hyperuricemia and metabolic syndrome.6 Increased dietary intake of such sugars can lead to fat production and obesity.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: Arthritis, diabetes, Gout, hypertension, hyperuricemia, kidney stones, Research, rheumatology, risk, Treatment, Uric acid, vascular diseaseIssue: August 2016

You Might Also Like:
  • Letter: Should We Monitor Asymptomatic Hyperuricemia?
  • Apolipoprotein E Polymorphism Associated with Hyperuricemia in Chinese Population
  • Weight Loss Surgery May Reduce Risk of Developing Gout
  • Prevalence of Gout and Hyperuricemia Increase in U.S.

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.